Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00375401 · ClinicalTrials.gov registry record · Phase 3
A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,536
- Enrollment target
NCT00375401: Clinical Trial Phase 3 study, sponsored by Pfizer.
NCT00375401 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,536 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00375401, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,536 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
Interventions
- DRUG Placebo
- DRUG CP-945,598 Treatment B
- DRUG CP-945,598 Treatment A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,536 participants |
| Start Date | 2006-10 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Why NCT00375401 stopped before completion
NCT00375401 is an interventional study that assigns participants to a tested intervention. Its 2,536 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (228% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00375401 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00375401 about?
NCT00375401 is a clinical study titled "A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety". The purpose of this study is to examine the long-term weight loss and safety of CP-945,598 in obese adults
What is the current status of trial NCT00375401?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,536 participants. The study started on 2006-10. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00375401?
The interventions under investigation include: Placebo (DRUG), CP-945,598 Treatment B (DRUG), CP-945,598 Treatment A (DRUG).
Who is sponsoring clinical trial NCT00375401?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00375401's enrollment target sits among peer trials
2,536 87th of 2000 higher than 1,914 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05931276 · 2,540 participants · Phase 3
CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes
- NCT00018057 · 2,530 participants · Phase 2
Study of Neuro-Cognitive Correlates of Pediatric Anxiety Disorders
- NCT04142177 · 2,529 participants · NA
Sequential and Comparative Evaluation of Pain Treatment Effectiveness Response
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia